TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26446930

Group type: EXPERIMENTAL
Intervention: He-Ne laser irradiation (632.8 nm, 10 mw, 6 j/cm² density)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (device powered off)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: He-Ne laser irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22183134

Group type: EXPERIMENTAL
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in DMT2 subjects
Number of subjects: 266

Group type: COMPARATOR
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in control group
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in entire population
Number of subjects: 266
Study: 21623389

Group type: EXPERIMENTAL
Intervention: Combined infusion of propofol and remifentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine jelly
Number of subjects: 100
Study: 19936371

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study: 17013734

Group type: EXPERIMENTAL
Intervention: Unipedal standing balance exercise (1 min, 3 times per day)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Unipedal standing balance exercise
Number of subjects: 553
Study: 12724021

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with ten different estrogen or estrogen‐progestin molecules, regimens and routes of administration
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: HRT with progestin molecules (except for 19‐nor derivatives) added to transdermal estradiol administration
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: DHEA levels
Number of subjects: 186
Study: 11061055

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and atenolol
Number of subjects: 351
Study: 9011896

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 39
Study: 1424937

Group type: EXPERIMENTAL
Intervention: Generalized decision tree or clinical algorithm for treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supranormal oxygen transport values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac index (CI), oxygen delivery (DO2), and oxygen consumption (VO2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Customized algorithms and individualized decision analysis
Number of subjects: 0
Study: 3909587

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy (azathioprine and steroids)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclosporin A combined with steroids
Number of subjects: 165
Study: 30393955

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy targeting LDL cholesterol <1.81 mmol/L
Number of subjects: 1909

Group type: COMPARATOR
Intervention: Standard statin therapy targeting LDL cholesterol ≥2.59 to <3.10 mmol/L
Number of subjects: 1909
Study: 29788920

Group type: EXPERIMENTAL
Intervention: Intervention group (COPE study)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 27309494

Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (high stress and anxiety)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition (no stress and anxiety)
Number of subjects: 36
Study: 25211775

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (details not specified)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 1260
Study: 21538074

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Long-term oral appliance use
Number of subjects: 103
Study: 20129008

Group type: EXPERIMENTAL
Intervention: 2-day educational seminar and monthly group guidance for 6 months
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 145
Study: 17369710

Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) measured by multifrequency bioelectrical impedance analysis in HD patients
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) measured by multifrequency bioelectrical impedance analysis in PD patients
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) in women HD patients
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) in women PD patients
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Nutritional status classification based on BPI in HD patients
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Correlation of BPI with serum albumin and transferrin concentrations
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: BPI in relation to dialysis history
Number of subjects: 448
Study: 15725144

Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nitroprusside (i.v.)
Number of subjects: 58
Study: 12059059

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 13288

Group type: EXPERIMENTAL
Intervention: Combination of FS and faecal occult blood test (FOBT)
Number of subjects: 13288

Group type: EXPERIMENTAL
Intervention: Overall attendance rate
Number of subjects: 13288

Group type: EXPERIMENTAL
Intervention: Screening in Telemark
Number of subjects: 13288

Group type: EXPERIMENTAL
Intervention: Screening in Oslo
Number of subjects: 13288
Study: 9864836

Group type: COMPARATOR
Intervention: TNFR55-IgG1 (2.5-100 mg/month, given i.v., cumulative doses from 40-940 mg)
Number of subjects: 80
Study: 8589768

Group type: EXPERIMENTAL
Intervention: casein-soy VLED (96 g protein, 1.7 MJ/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hydrolyzed collagen VLED (tryptophan- and methionine-supplemented)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: both VLEDs
Number of subjects: 6

Group type: COMPARATOR
Intervention: casein-soy VLED
Number of subjects: 6

Group type: COMPARATOR
Intervention: hydrolyzed collagen VLED
Number of subjects: 6
Study: 2184790

Group type: EXPERIMENTAL
Intervention: Physician recognition of depression (defined by chart notation or prescription of antidepressants)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Physician misdiagnosis of depression
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Self-report depression scales
Number of subjects: 265
Study: 6965176

Group type: EXPERIMENTAL
Intervention: Cognitive family therapy
Number of subjects: 11
Study: 31063856

Group type: EXPERIMENTAL
Intervention: Lifestyle focused text messaging intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 229
Study: 29166854

Group type: EXPERIMENTAL
Intervention: Ringer's lactate 10 mL containing dezocine 0.1 mg/kg (Group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ringer's lactate 10 mL (Group C)
Number of subjects: 100
Study: 26076191

Group type: EXPERIMENTAL
Intervention: Octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Octreotide LAR 30 mg
Number of subjects: 122
Study: 23591188

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) imaging
Number of subjects: 171

Group type: COMPARATOR
Intervention: Multislice computed tomography (MS-CT) angiography
Number of subjects: 171
Study: 20953864

Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parapatellar approach
Number of subjects: 40
Study: 19266107

Group type: EXPERIMENTAL
Intervention: Flavored supplement (Group 1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Non-flavored (neutral) supplement (Group 2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Kitchen foods as supplements (Group 3)
Number of subjects: 125

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 125

Group type: COMPARATOR
Intervention: Commercial supplemented groups (G1 and G2)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Energy requirements fulfillment
Number of subjects: 125
Study: 17056206

Group type: EXPERIMENTAL
Intervention: Medication coaching plus voucher reinforcement for opening electronic medication caps on time
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medication coaching sessions every other week (comparison group)
Number of subjects: 66
Study: 15377466

Group type: EXPERIMENTAL
Intervention: G‐CSF 5 micro g/kg/day (group A)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: G‐CSF 10 micro g/kg/day (group B)
Number of subjects: 77
Study: 11704164

Group type: EXPERIMENTAL
Intervention: Outpatient group (Foley catheter placement, discharged home)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Inpatient group (Foley catheter placement, admitted to labor and delivery)
Number of subjects: 111
Study: 9863077

Group type: EXPERIMENTAL
Intervention: 400 mg of artesunate tablet over 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 600 mg of artesunate tablet over 5 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 800 mg of artesunate tablet over 7 days
Number of subjects: 90
Study: 7910560

Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (S-28) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (S-14) infusion
Number of subjects: 0
Study: 3302248

Group type: EXPERIMENTAL
Intervention: d,alpha-tocopherol (400 IU daily for three cycles)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30076365

Group type: EXPERIMENTAL
Intervention: Infraslow neurofeedback (ISF-NF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28688961

Group type: EXPERIMENTAL
Intervention: Responsive familiarization
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Motionless familiarization
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active sleep duration
Number of subjects: 45
Study: 26406087

Group type: EXPERIMENTAL
Intervention: Pulse wave analysis during VDT operation
Number of subjects: 30
Study: 23769235

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir plus raltegravir
Number of subjects: 558

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus two or three NtRTIs (control group)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Raltegravir group
Number of subjects: 558
Study: 20940639

Group type: EXPERIMENTAL
Intervention: 1 minute rest interval
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 minute rest interval
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 17
Study: 18443980

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (typical or atypical)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 0
Study: 15681940

Group type: EXPERIMENTAL
Intervention: 75 U/kg recombinant human antithrombin (rhAT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 54
Study: 14555373

Group type: EXPERIMENTAL
Intervention: Tiredness
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Stomach ache
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Backache
Number of subjects: 1155
Study: 10541927

Group type: EXPERIMENTAL
Intervention: Submaximal treadmill exercise at 7, 8, and 9 km/h for 4 minutes at 0800, 1300, and 1700 hours.
Number of subjects: 21
Study: 8727528

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11188584

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression scale (CES-D)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: General Well-Being Schedule depression subscale (GWB-D)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control subjects (57 age-matched)
Number of subjects: 41
Study: 7048880

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pindolol 60 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pindolol (mean dose 50 mg/day)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Propranolol (mean 360 mg/day)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (mean 107 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 31393146

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) delivered by JPOs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probation services as usual (PAU)
Number of subjects: 0
Study: 31148589

Group type: EXPERIMENTAL
Intervention: Dietary micronutrient intakes
Number of subjects: 6426
Study: 28633170

Group type: EXPERIMENTAL
Intervention: Web-based module outlining genetic concepts applied to CRC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Live presentation of the web-based material
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Live presentation and subsequent standardized patient (SP) encounter
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study: 26070699

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 87

Group type: COMPARATOR
Intervention: NPH (Neutral Protamine Hagedorn)
Number of subjects: 87
Study: 23711593

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol and Mitiglinide combination
Number of subjects: 0
Study: 19823804

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (RTD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 9
Study: 19848210

Group type: EXPERIMENTAL
Intervention: Flos Magnoliae volatile oil nano-liposome nasal drops (FMO)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 191
Study: 17531698

Group type: EXPERIMENTAL
Intervention: Low-intensity UVA irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical polishing
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 15042308

Group type: EXPERIMENTAL
Intervention: Cuff Pressure Control (Tracoe) device; target pressure of 25.5 cmH(2)O
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional handheld manometer; pressures kept between 20 cmH(2)O and 40 cmH(2)O
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups (automatic and conventional)
Number of subjects: 80
Study: 11535206

Group type: EXPERIMENTAL
Intervention: EE/LNG 20/100
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: EE/NET 20/500
Number of subjects: 767

Group type: COMPARATOR
Intervention: EE/LNG 30/150
Number of subjects: 767
Study: 9784769

Group type: EXPERIMENTAL
Intervention: Prophylactic epoetin alfa therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Blood transfusions
Number of subjects: 50
Study: 8068601

Group type: EXPERIMENTAL
Intervention: ApoE ε2 allele
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: ApoE ε4 allele
Number of subjects: 574

Group type: COMPARATOR
Intervention: ApoE E3/3 phenotype
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Presence of ε2 allele
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Presence of ε4 allele
Number of subjects: 574
Study: 3073077

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) plus Nifedipine (10 mg three times/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-Atenolol
Number of subjects: 10
Study: 31269116

Group type: EXPERIMENTAL
Intervention: Non‐EWBT + three‐step etch‐and‐rinse (Scotchbond Multi Purpose, 3M ESPE)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: EWBT + Scotchbond Multi Purpose (MP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: EWBT + Bond (third step of MP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: EWBT + universal adhesive (Single Bond Universal, 3M ESPE)
Number of subjects: 148
Study: 27879326

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 131

Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 131

Group type: COMPARATOR
Intervention: TPOAb-negative group (Control Group C)
Number of subjects: 131
Study: 26679186

Group type: EXPERIMENTAL
Intervention: Face-to-face instructor-led program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hybrid program with alternating face-to-face and mobile technology-delivered content
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both intervention formats combined
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face-to-face vs hybrid format
Number of subjects: 60
Study: 23224142

Group type: EXPERIMENTAL
Intervention: Antioxidant-enriched enteral nutrition (AeEN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral nutrition (IeEN)
Number of subjects: 20
Study: 21510896

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined CT and PRT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham interventions (educational videos and seated calisthenics)
Number of subjects: 132
Study: 19065862

Group type: EXPERIMENTAL
Intervention: Multiracial faces given European names
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiracial faces given Asian names
Number of subjects: 0
Study: 16781360

Group type: EXPERIMENTAL
Intervention: eptifibatide + reduced dose unfractionated heparin (n = 298)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: eptifibatide + reduced-dose enoxaparin (n = 275)
Number of subjects: 857

Group type: COMPARATOR
Intervention: bivalirudin monotherapy (n = 284)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 857
Study: 14586603

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitative treatment for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ordinary rehabilitative treatment for 14 days
Number of subjects: 60
Study: 11056254

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy (OHS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saline infusion hysterosonography (SIS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) and Outpatient hysteroscopy (OHS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) and Saline infusion hysterosonography (SIS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Outpatient hysteroscopy (OHS) and Saline infusion hysterosonography (SIS)
Number of subjects: 46
Study: 8816211

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (cumulative phospholipid dose of 200 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (single dose of 100 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated controls (17 infants)
Number of subjects: 40
Study: 1409770

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation (10 mg, 100 mg, 1000 mg, 10,000 mg EPA daily; 3 mg, 33 mg, 333 mg, 3333 mg DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil as placebo
Number of subjects: 0
Study: 2934264

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30891808

Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression
Number of subjects: 1981

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 1981
Study: 27400939

Group type: EXPERIMENTAL
Intervention: ATRA-ATO
Number of subjects: 276

Group type: COMPARATOR
Intervention: ATRA-CHT
Number of subjects: 276
Study: 26327799

Group type: EXPERIMENTAL
Intervention: Pre-operative ibuprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early post-operative ibuprofen 400 mg
Number of subjects: 0
Study: 25674254

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (uploading blood glucose and metabolic information at home every 2 weeks, with a follow-up interval of 3 months)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Traditional face-to-face visit (control group)
Number of subjects: 114
Study: 20832196

Group type: EXPERIMENTAL
Intervention: Directly observed antiretroviral therapy (DOT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Self-administered therapy (Control)
Number of subjects: 77
Study: 19018794

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of TAC and 5-fluorouracil (5-FU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (TAC)
Number of subjects: 40
Study: 17463116

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 26
Study: 15220172

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway insertion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oropharyngeal airway insertion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24